NCT04699838View on ClinicalTrials.gov

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG

Cisplatin

Cisplatin

DRUG

Carboplatin

Carboplatin

DRUG

Etoposide

Etoposide

DRUG

Durvalumab

Durvalumab

DRUG

Ceralasertib

Ceralasertib

Trial Locations (5)

21201

RECRUITING

University of Maryland, Baltimore

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

52242

RECRUITING

University of Iowa Hospitals and Clinics, Iowa City

60612

RECRUITING

University of Illinois Medical Center, Chicago

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Muhammad Furqan

OTHER